Brian E. Lewis MD, MPH, FACP
Assistant Professor of Clinical Medicine, Department of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LouisianaBiographical Sketch:
Dr. Brian Lewis is an Assistant Professor of Clinical Medicine in the Department of Hematology and Medical Oncology at Tulane University School of Medicine in New Orleans. He is also the Chair of the Fellowship Advancement Committee of the Hematology and Medical Oncology Fellowship Program at Tulane.
Following his graduation from George Mason University in Fairfax, Virginia, Dr. Lewis enrolled in the Tulane University School of Public Health and, upon completing his MPH degree, entered medical school at Tulane. He completed his medical degree and residency training in internal medicine at Tulane, where he also completed his fellowship in hematology and medical oncology.
Dr. Lewis is a member of several professional societies, including the American Society of Hematology and the American Society of Clinical Oncology. Dr. Lewis is a Fellow of the American College of Physicians.
Positions:
Assistant Professor of Clinical Medicine, Department of Hematology and Medical Oncology; Chair, Fellowship Advancement Committee, Hematology and Medical Oncology Fellowship Program, Tulane University School of Medicine
Degrees:
MPH: Tulane University School of Public Health, New Orleans, Louisiana
MD: Tulane University School of Medicine
Disclosures
Dr. Brian Lewis does not have any financial interests to disclose.
Recent Contributions to PracticeUpdate:
- Improved Prognostic Utility of a New mRNA Expression Signature of Gleason Score
- ESMO 2016: Recommendations From Dr. Brian E. Lewis
- Adverse Events With Prednisone Plus Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
- Improved Survival Benefit With Increased Docetaxel Cycles in Prostate Cancer
- ASCO 2016: Dr. Brian Lewis’s Abstract Recommendations—Prostate Cancer
- Addition of Docetaxel to Androgen Deprivation Therapy in Patients With Hormone-Sensitive Metastatic Prostate Cancer
- Enzalutamide for Older Patients With Metastatic Castration-Resistant Prostate Cancer
- Evaluating an Elevated Screening PSA Test
- USPSTF Screening Recommendations and Impact on Prostate Cancer Incidence and PSA Testing
- Effect of the Recommendation Against Screening on Prostate Cancer Diagnoses